Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - possia, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-st-elevation myocardial infarction [nstemi] or st-elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - ticagrelor - tablet - 90mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - ticagrelor - tablet - 60mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - ticagrelor - orodispersible tablet - 90mg

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - ticagrelor 60 mg

Israel - English - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - brilique, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (acs) ora history of myocardial infarction (mi) and a high risk of developing an atherothrombotic eventbrilique, co-administered with acetyl salicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Canada - English - Health Canada

astrazeneca canada inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

Canada - English - Health Canada

astrazeneca canada inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors